Primary bone lymphoma: Evaluation of chemoimmunotherapy as front-line treatment in 21 patients

Cinzia Pellegrini, Letizia Gandolfi, Federica Quirini, Pietro Ruggieri, Vittorio Stefoni, Enrico Derenzini, Alessandro Broccoli, Lisa Argnani, Stefano Pileri, Mario Mercuri, Michele Baccarani, Pier Luigi Zinzani

Research output: Contribution to journalArticlepeer-review


Background: We performed a retrospective investigation to assess the efficacy of chemotherapy and rituximab as front-line treatment for primary bone lymphoma (PBL). Patients and Methods: Between 1999 and 2009, 21 previously untreated patients received a diagnosis of PBL. All the patients were treated with anthracycline-containing chemotherapeutic regimens, with the addition of rituximab; 11 patients received consolidative radiation therapy after induction treatment. Results: Patients' median age was 34 years (range, 18-82 years); all presented with diffuse large B-cell lymphoma. Complete responses were seen in 95.2% of the patients treated. No relapses were observed at a median follow-up of 43.9 months. Eight-year overall survival and disease-free survival were 95.2% and 100.0%, respectively. Conclusion: These data indicate that the combined chemotherapy plus rituximab treatment may represent a suitable front-line approach in PBL, with a high rate of responses and an excellent long-term survival.

Original languageEnglish
Pages (from-to)321-325
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number4
Publication statusPublished - Aug 2011


  • Anthracycline-containing regimen
  • Chemotherapy
  • Orthopedics
  • Primary bone lymphoma
  • Radiotherapy
  • Rituximab

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology
  • Medicine(all)


Dive into the research topics of 'Primary bone lymphoma: Evaluation of chemoimmunotherapy as front-line treatment in 21 patients'. Together they form a unique fingerprint.

Cite this